Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Razvan Cristescu

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Oncotarget|October 15, 2017
Development of mesenchymal subtype gene signature for clinical application in gastric cancerJeeyun Lee, Razvan Cristescu, Kyoung-Mee Kim, et al.
Cancer Medicine|June 12, 2024
Prevalence and prognosis of hypoxia-inducible factor-2α (HIF-2α) pathway gene mutations across advanced solid tumorsWenjun Zhong, Jiemin Ma, Cai Chen, et al.
Prostate Cancer and Prostatic Diseases|December 6, 2023
Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databasesIrene M Shui, Mehmet Burcu, Changxia Shao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2018
Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as MonotherapyMark Ayers, Michael Nebozhyn, Razvan Cristescu, et al.
Future Oncology (London, England)|July 16, 2024
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational studyCai Chen, Elisha J Dettman, Wei Zhou, et al.
Journal of Gynecologic Oncology|June 10, 2024
Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancerMin-Hyun Baek, Lei Chen, Cumhur Tekin, et al.
Advances in Therapy|January 3, 2024
Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database StudyChangxia Shao, Yixin Ren, Heng Zhou, et al.
JCO Precision Oncology|November 16, 2023
Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid TumorsChangxia Shao, Yixin Ren, Heng Zhou, et al.
Pathology, Research and Practice|February 25, 2020
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular featuresXiaoqiao Liu, Min Gew Choi, Kyung Kim, et al.
The Journal of Molecular Diagnostics : JMD|February 26, 2022
Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to PembrolizumabBo Wei, John Kang, Miho Kibukawa, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Oncotarget|October 15, 2017
Development of mesenchymal subtype gene signature for clinical application in gastric cancerJeeyun Lee, Razvan Cristescu, Kyoung-Mee Kim, et al.
Cancer Medicine|June 12, 2024
Prevalence and prognosis of hypoxia-inducible factor-2α (HIF-2α) pathway gene mutations across advanced solid tumorsWenjun Zhong, Jiemin Ma, Cai Chen, et al.
Prostate Cancer and Prostatic Diseases|December 6, 2023
Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databasesIrene M Shui, Mehmet Burcu, Changxia Shao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2018
Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as MonotherapyMark Ayers, Michael Nebozhyn, Razvan Cristescu, et al.
Future Oncology (London, England)|July 16, 2024
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational studyCai Chen, Elisha J Dettman, Wei Zhou, et al.
Journal of Gynecologic Oncology|June 10, 2024
Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancerMin-Hyun Baek, Lei Chen, Cumhur Tekin, et al.
Advances in Therapy|January 3, 2024
Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database StudyChangxia Shao, Yixin Ren, Heng Zhou, et al.
JCO Precision Oncology|November 16, 2023
Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid TumorsChangxia Shao, Yixin Ren, Heng Zhou, et al.
Pathology, Research and Practice|February 25, 2020
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular featuresXiaoqiao Liu, Min Gew Choi, Kyung Kim, et al.
The Journal of Molecular Diagnostics : JMD|February 26, 2022
Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to PembrolizumabBo Wei, John Kang, Miho Kibukawa, et al.
Pageof 6